Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke

Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Free radical biology & medicine 2013-09, Vol.62, p.26-36
Hauptverfasser: Speer, Rachel E., Karuppagounder, Saravanan S., Basso, Manuela, Sleiman, Sama F., Kumar, Amit, Brand, David, Smirnova, Natalya, Gazaryan, Irina, Khim, Soah J., Ratan, Rajiv R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 36
container_issue
container_start_page 26
container_title Free radical biology & medicine
container_volume 62
creator Speer, Rachel E.
Karuppagounder, Saravanan S.
Basso, Manuela
Sleiman, Sama F.
Kumar, Amit
Brand, David
Smirnova, Natalya
Gazaryan, Irina
Khim, Soah J.
Ratan, Rajiv R.
description Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside. Hypoxia-inducible factor (HIF)-1α mediates a broad, evolutionarily conserved, endogenous adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective in a number of human neurological diseases and experimental models. In this review, we discuss molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further, we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal chelators on ferroptosis in vitro as well in animal models of neurological diseases. [Display omitted] ► Adaptation to hypoxia has evolved over billions of years. ► HIF prolyl hydroxylases are sensors of hypoxia. ► Antioxidant “metal chelators” inhibit HIF prolyl hydroxylases. ► Prolyl hydroxylase inhibitors prevent death via HIF-dependent and independent paths. ► Prolyl hydroxylase inhibitors prevent ferroptosis and stroke.
doi_str_mv 10.1016/j.freeradbiomed.2013.01.026
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4327984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0891584913000361</els_id><sourcerecordid>1412161643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c581t-f3e5236728798c6976d518f1d36ca27ac4f8c012945f84f57c1ac9cc66082e953</originalsourceid><addsrcrecordid>eNqNkc9u1DAQhyMEotvCK4AlLlwS_Cd2HJCQUNVSpEocoGfL64x3vSTxYjvV5tYH4BHKy_VJ8GpLRW-cRpa_-WY0v6J4Q3BFMBHvNpUNAEF3S-cH6CqKCaswqTAVT4oFkQ0ra96Kp8UCy5aUXNbtUXEc4wZjXHMmnxdHlLFGYEYXxa-Leet3Tpdu7Cbjlj0gq03yAW2D7-cerecu-N3c6wgR6YiSDitIEdmMjDAFn7kEJjk_ouWM7m5u9ZgfO9flenfzGw2QdI_MGnqdtfE9Og9-QBZCbk0-uqz0KKbgf8CL4pnVfYSX9_WkuDo_-356UV5-_fzl9NNlabgkqbQMOGWiobJppRFtIzpOpCUdE0bTRpvaSoMJbWtuZW15Y4g2rTFCYEmh5eyk-HjwbqdlvqCBMQXdq21wgw6z8tqpxz-jW6uVv1Y1o3lknQVv7wXB_5wgJjW4aKDv9Qh-iorUhBJBRM0y-uGAmuBjDGAfxhCs9nmqjXqUp9rnqTBROc_c_erfTR96_waYgdcHwGqv9Cq4qK6-ZQPH2dIwvl_g7EBAvui1g6CicTAa6FzIuanOu_9a5Q84kMln</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1412161643</pqid></control><display><type>article</type><title>Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Speer, Rachel E. ; Karuppagounder, Saravanan S. ; Basso, Manuela ; Sleiman, Sama F. ; Kumar, Amit ; Brand, David ; Smirnova, Natalya ; Gazaryan, Irina ; Khim, Soah J. ; Ratan, Rajiv R.</creator><creatorcontrib>Speer, Rachel E. ; Karuppagounder, Saravanan S. ; Basso, Manuela ; Sleiman, Sama F. ; Kumar, Amit ; Brand, David ; Smirnova, Natalya ; Gazaryan, Irina ; Khim, Soah J. ; Ratan, Rajiv R.</creatorcontrib><description>Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside. Hypoxia-inducible factor (HIF)-1α mediates a broad, evolutionarily conserved, endogenous adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective in a number of human neurological diseases and experimental models. In this review, we discuss molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further, we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal chelators on ferroptosis in vitro as well in animal models of neurological diseases. [Display omitted] ► Adaptation to hypoxia has evolved over billions of years. ► HIF prolyl hydroxylases are sensors of hypoxia. ► Antioxidant “metal chelators” inhibit HIF prolyl hydroxylases. ► Prolyl hydroxylase inhibitors prevent death via HIF-dependent and independent paths. ► Prolyl hydroxylase inhibitors prevent ferroptosis and stroke.</description><identifier>ISSN: 0891-5849</identifier><identifier>EISSN: 1873-4596</identifier><identifier>DOI: 10.1016/j.freeradbiomed.2013.01.026</identifier><identifier>PMID: 23376032</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer disease ; animal models ; antioxidants ; Antioxidants - metabolism ; Antioxidants - therapeutic use ; chelating agents ; Chelating Agents - metabolism ; death ; Free radicals ; Humans ; Hypoxia ; Hypoxia-Inducible Factor 1 - antagonists &amp; inhibitors ; Hypoxia-Inducible Factor 1 - metabolism ; Hypoxia-inducible factors ; Metal chelators ; Metals - metabolism ; Molecular Targeted Therapy ; Neurodegeneration ; Neuroprotective Agents - metabolism ; Neuroprotective Agents - therapeutic use ; neuroprotective effect ; Oxidative Stress ; Parkinson disease ; procollagen-proline dioxygenase ; Prolyl hydroxylases ; stroke ; Stroke - drug therapy ; Stroke - enzymology ; Stroke - pathology ; therapeutics ; Transcription</subject><ispartof>Free radical biology &amp; medicine, 2013-09, Vol.62, p.26-36</ispartof><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c581t-f3e5236728798c6976d518f1d36ca27ac4f8c012945f84f57c1ac9cc66082e953</citedby><cites>FETCH-LOGICAL-c581t-f3e5236728798c6976d518f1d36ca27ac4f8c012945f84f57c1ac9cc66082e953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.freeradbiomed.2013.01.026$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23376032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Speer, Rachel E.</creatorcontrib><creatorcontrib>Karuppagounder, Saravanan S.</creatorcontrib><creatorcontrib>Basso, Manuela</creatorcontrib><creatorcontrib>Sleiman, Sama F.</creatorcontrib><creatorcontrib>Kumar, Amit</creatorcontrib><creatorcontrib>Brand, David</creatorcontrib><creatorcontrib>Smirnova, Natalya</creatorcontrib><creatorcontrib>Gazaryan, Irina</creatorcontrib><creatorcontrib>Khim, Soah J.</creatorcontrib><creatorcontrib>Ratan, Rajiv R.</creatorcontrib><title>Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke</title><title>Free radical biology &amp; medicine</title><addtitle>Free Radic Biol Med</addtitle><description>Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside. Hypoxia-inducible factor (HIF)-1α mediates a broad, evolutionarily conserved, endogenous adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective in a number of human neurological diseases and experimental models. In this review, we discuss molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further, we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal chelators on ferroptosis in vitro as well in animal models of neurological diseases. [Display omitted] ► Adaptation to hypoxia has evolved over billions of years. ► HIF prolyl hydroxylases are sensors of hypoxia. ► Antioxidant “metal chelators” inhibit HIF prolyl hydroxylases. ► Prolyl hydroxylase inhibitors prevent death via HIF-dependent and independent paths. ► Prolyl hydroxylase inhibitors prevent ferroptosis and stroke.</description><subject>Alzheimer disease</subject><subject>animal models</subject><subject>antioxidants</subject><subject>Antioxidants - metabolism</subject><subject>Antioxidants - therapeutic use</subject><subject>chelating agents</subject><subject>Chelating Agents - metabolism</subject><subject>death</subject><subject>Free radicals</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Hypoxia-Inducible Factor 1 - antagonists &amp; inhibitors</subject><subject>Hypoxia-Inducible Factor 1 - metabolism</subject><subject>Hypoxia-inducible factors</subject><subject>Metal chelators</subject><subject>Metals - metabolism</subject><subject>Molecular Targeted Therapy</subject><subject>Neurodegeneration</subject><subject>Neuroprotective Agents - metabolism</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>neuroprotective effect</subject><subject>Oxidative Stress</subject><subject>Parkinson disease</subject><subject>procollagen-proline dioxygenase</subject><subject>Prolyl hydroxylases</subject><subject>stroke</subject><subject>Stroke - drug therapy</subject><subject>Stroke - enzymology</subject><subject>Stroke - pathology</subject><subject>therapeutics</subject><subject>Transcription</subject><issn>0891-5849</issn><issn>1873-4596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQhyMEotvCK4AlLlwS_Cd2HJCQUNVSpEocoGfL64x3vSTxYjvV5tYH4BHKy_VJ8GpLRW-cRpa_-WY0v6J4Q3BFMBHvNpUNAEF3S-cH6CqKCaswqTAVT4oFkQ0ra96Kp8UCy5aUXNbtUXEc4wZjXHMmnxdHlLFGYEYXxa-Leet3Tpdu7Cbjlj0gq03yAW2D7-cerecu-N3c6wgR6YiSDitIEdmMjDAFn7kEJjk_ouWM7m5u9ZgfO9flenfzGw2QdI_MGnqdtfE9Og9-QBZCbk0-uqz0KKbgf8CL4pnVfYSX9_WkuDo_-356UV5-_fzl9NNlabgkqbQMOGWiobJppRFtIzpOpCUdE0bTRpvaSoMJbWtuZW15Y4g2rTFCYEmh5eyk-HjwbqdlvqCBMQXdq21wgw6z8tqpxz-jW6uVv1Y1o3lknQVv7wXB_5wgJjW4aKDv9Qh-iorUhBJBRM0y-uGAmuBjDGAfxhCs9nmqjXqUp9rnqTBROc_c_erfTR96_waYgdcHwGqv9Cq4qK6-ZQPH2dIwvl_g7EBAvui1g6CicTAa6FzIuanOu_9a5Q84kMln</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Speer, Rachel E.</creator><creator>Karuppagounder, Saravanan S.</creator><creator>Basso, Manuela</creator><creator>Sleiman, Sama F.</creator><creator>Kumar, Amit</creator><creator>Brand, David</creator><creator>Smirnova, Natalya</creator><creator>Gazaryan, Irina</creator><creator>Khim, Soah J.</creator><creator>Ratan, Rajiv R.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130901</creationdate><title>Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke</title><author>Speer, Rachel E. ; Karuppagounder, Saravanan S. ; Basso, Manuela ; Sleiman, Sama F. ; Kumar, Amit ; Brand, David ; Smirnova, Natalya ; Gazaryan, Irina ; Khim, Soah J. ; Ratan, Rajiv R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c581t-f3e5236728798c6976d518f1d36ca27ac4f8c012945f84f57c1ac9cc66082e953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer disease</topic><topic>animal models</topic><topic>antioxidants</topic><topic>Antioxidants - metabolism</topic><topic>Antioxidants - therapeutic use</topic><topic>chelating agents</topic><topic>Chelating Agents - metabolism</topic><topic>death</topic><topic>Free radicals</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Hypoxia-Inducible Factor 1 - antagonists &amp; inhibitors</topic><topic>Hypoxia-Inducible Factor 1 - metabolism</topic><topic>Hypoxia-inducible factors</topic><topic>Metal chelators</topic><topic>Metals - metabolism</topic><topic>Molecular Targeted Therapy</topic><topic>Neurodegeneration</topic><topic>Neuroprotective Agents - metabolism</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>neuroprotective effect</topic><topic>Oxidative Stress</topic><topic>Parkinson disease</topic><topic>procollagen-proline dioxygenase</topic><topic>Prolyl hydroxylases</topic><topic>stroke</topic><topic>Stroke - drug therapy</topic><topic>Stroke - enzymology</topic><topic>Stroke - pathology</topic><topic>therapeutics</topic><topic>Transcription</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Speer, Rachel E.</creatorcontrib><creatorcontrib>Karuppagounder, Saravanan S.</creatorcontrib><creatorcontrib>Basso, Manuela</creatorcontrib><creatorcontrib>Sleiman, Sama F.</creatorcontrib><creatorcontrib>Kumar, Amit</creatorcontrib><creatorcontrib>Brand, David</creatorcontrib><creatorcontrib>Smirnova, Natalya</creatorcontrib><creatorcontrib>Gazaryan, Irina</creatorcontrib><creatorcontrib>Khim, Soah J.</creatorcontrib><creatorcontrib>Ratan, Rajiv R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Free radical biology &amp; medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Speer, Rachel E.</au><au>Karuppagounder, Saravanan S.</au><au>Basso, Manuela</au><au>Sleiman, Sama F.</au><au>Kumar, Amit</au><au>Brand, David</au><au>Smirnova, Natalya</au><au>Gazaryan, Irina</au><au>Khim, Soah J.</au><au>Ratan, Rajiv R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke</atitle><jtitle>Free radical biology &amp; medicine</jtitle><addtitle>Free Radic Biol Med</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>62</volume><spage>26</spage><epage>36</epage><pages>26-36</pages><issn>0891-5849</issn><eissn>1873-4596</eissn><abstract>Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside. Hypoxia-inducible factor (HIF)-1α mediates a broad, evolutionarily conserved, endogenous adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective in a number of human neurological diseases and experimental models. In this review, we discuss molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further, we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal chelators on ferroptosis in vitro as well in animal models of neurological diseases. [Display omitted] ► Adaptation to hypoxia has evolved over billions of years. ► HIF prolyl hydroxylases are sensors of hypoxia. ► Antioxidant “metal chelators” inhibit HIF prolyl hydroxylases. ► Prolyl hydroxylase inhibitors prevent death via HIF-dependent and independent paths. ► Prolyl hydroxylase inhibitors prevent ferroptosis and stroke.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23376032</pmid><doi>10.1016/j.freeradbiomed.2013.01.026</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0891-5849
ispartof Free radical biology & medicine, 2013-09, Vol.62, p.26-36
issn 0891-5849
1873-4596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4327984
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Alzheimer disease
animal models
antioxidants
Antioxidants - metabolism
Antioxidants - therapeutic use
chelating agents
Chelating Agents - metabolism
death
Free radicals
Humans
Hypoxia
Hypoxia-Inducible Factor 1 - antagonists & inhibitors
Hypoxia-Inducible Factor 1 - metabolism
Hypoxia-inducible factors
Metal chelators
Metals - metabolism
Molecular Targeted Therapy
Neurodegeneration
Neuroprotective Agents - metabolism
Neuroprotective Agents - therapeutic use
neuroprotective effect
Oxidative Stress
Parkinson disease
procollagen-proline dioxygenase
Prolyl hydroxylases
stroke
Stroke - drug therapy
Stroke - enzymology
Stroke - pathology
therapeutics
Transcription
title Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T00%3A28%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypoxia-inducible%20factor%20prolyl%20hydroxylases%20as%20targets%20for%20neuroprotection%20by%20%E2%80%9Cantioxidant%E2%80%9D%20metal%20chelators:%20From%20ferroptosis%20to%20stroke&rft.jtitle=Free%20radical%20biology%20&%20medicine&rft.au=Speer,%20Rachel%20E.&rft.date=2013-09-01&rft.volume=62&rft.spage=26&rft.epage=36&rft.pages=26-36&rft.issn=0891-5849&rft.eissn=1873-4596&rft_id=info:doi/10.1016/j.freeradbiomed.2013.01.026&rft_dat=%3Cproquest_pubme%3E1412161643%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1412161643&rft_id=info:pmid/23376032&rft_els_id=S0891584913000361&rfr_iscdi=true